Coronavirus Update: Inside Moderna's Deal With The US

Plus: Generex Forges Vaccine Partnership

19 Aug 2020

• By Scrip Team

Company receives a base payment of $1.225bn for the manufacturing and delivery of the first 100 million disease, plus a bonus if mRNA-1273 reaches the market quickly.

A cyclist wearing a mask in New York's Times Square.

An 8-K filing with the US Securities and Exchange Commission has pulled back the blinds on the deal Moderna, Inc. reached to supply the US with its COVID-19 vaccine mRNA-1273. On 11 August, the company announced it had signed a deal with the US Department of Defense to provide an initial 100 million doses of the vaccine for $1.525bn.

That includes a base payment of $1.225bn for the manufacturing and delivery of the first 100 million disease, plus a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Altimmune’s Phase IIb MASH Data Send Share Price Plunging

27 Jun 2025

• By Joseph Haas

Altimmune’s stock price did not recover on June 27, after a 57% dip the day before, despite efforts to position pemvidutide as both resolving MASH and offering weight loss.

Deal Watch: Novartis To Develop Cardiovascular Therapies With ProFound

27 Jun 2025

• By Joseph Haas, Sushmita Panda, Jung Won Shin, and Alaric DeArment

Plus deals involving BioCryst/Neopharmed Gentili, Sanofi/Kymera, Abion, Denovo/Chuang Yi, Carisma/OrthoCellix, Otsuka/Harbour Biomed, Aptose/Hanmi, Philochem/RayzeBio, Concentra/Elevation Oncology, and more.